Gilligan M, McGuigan C, McKeon A. Paraneoplastic neurologic disorders. Curr Neurol Neurosci Rep. 2023;23(3):67–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vogrig A, Gigli GL, Segatti S, Corazza E, Marini A, Bernardini A, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020;267:26–35. The first epidemiology study looking at prevalence and incidence of paraneoplastic neoplasic disorders, which showed higher prevalence than previously recognized.

Article  CAS  PubMed  Google Scholar 

Marsili L, Marcucci S, LaPorta J, Chirra M, Espay AJ, Colosimo C. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines. 2023;11(5):1406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graus F, Vogrig A, Muñiz-Castrillo S, Antoine J-CG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol-Neuroimmunol Neuroinflammation. 2021;8(4):e1014. This article provides an updated classification and diagnosis criteria for paraneoplastic syndromes.

Graus F, Delattre J, Antoine JE, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai M-T, Qiao S, Lai Q-L, Zheng Y, Yang F, Fang G-L, et al. Evaluation of the updated diagnostic criteria for paraneoplastic neurologic syndromes in China. Front Immunol. 2022;13:790400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viaccoz A, Honnorat J. Paraneoplastic neurological syndromes: general treatment overview. Curr Treat Options Neurol. 2013;15:150–68.

Article  PubMed  Google Scholar 

Devine MF, Kothapalli N, Elkhooly M, Dubey D. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord. 2021;14:1756286420985323.

Article  PubMed  PubMed Central  Google Scholar 

Binks S, Uy C, Honnorat J, Irani SR. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2022;22(1):19–31.

Article  PubMed  Google Scholar 

Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K. Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol. 2019;10(3):346–52.

Article  Google Scholar 

Agrawal K, Agrawal N. Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer. Case Rep Neurol Med. 2019;2019.

Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e604.

Sechi E, Markovic SN, McKeon A, Dubey D, Liewluck T, Lennon VA, et al. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology. 2020;95(17):e2442–52. An important study that describes neuroautoimmune disorders that were triggered by immune checkpoiny inhibitor ICI cancer immunotherapy.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffmann L, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008;79(7):767–73.

Article  CAS  PubMed  Google Scholar 

Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(6):1138–48.

Article  CAS  PubMed  Google Scholar 

Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M. Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist. 2018;23(1):118–20.

Article  PubMed  Google Scholar 

Camdessanché J-P, Antoine J-C, Honnorat J, Vial C, Petiot P, Convers P, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. J Peripher Nerv Syst. 2002;7(3):207.

Article  Google Scholar 

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, et al. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2018;89(7):789–92.

Article  PubMed  Google Scholar 

Gill A, Perez MA, Perrone CM, Bae CJ, Pruitt AA, Lancaster E. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol. 2019;334:576980.

Article  CAS  PubMed  Google Scholar 

Peterson K, Rosenblum M, Kotanides H, Posner J. Paraneoplastic cerebellar degeneration.: IA clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931.

Article  CAS  PubMed  Google Scholar 

McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ, Lennon VA. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol. 2011;68(10):1282–9.

Article  PubMed  Google Scholar 

Farina A, Rogemond V, Peter E, Wucher V, Garcia MV, Picard G, et al. Anti-Yo autoimmunity in patients with post-immune checkpoint inhibitors neurological syndromes (P4–5.027). AAN Enterprises. 2023;100(17_supplement_2).

Yu Z, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146–54.

Article  CAS  PubMed  Google Scholar 

Dubey D, Lennon VA, Gadoth A, Pittock SJ, Flanagan EP, Schmeling JE, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103–10.

Article  CAS  PubMed  Google Scholar 

Dubey D, Jitprapaikulsan J, Bi H, Do Campo RV, McKeon A, Pittock SJ, et al. Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873–80.

Article  CAS  PubMed  Google Scholar 

Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71(24):1955–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58(1):96–107.

Article  PubMed  Google Scholar 

Iwanaga Y, Kawaguchi T, Yamasaki K, Sato T, Kubo N, Morimoto T, et al. Fatal limbic encephalitis as paraneoplastic neurological syndrome in a patient with lung adenocarcinoma positive for antiamphiphysin antibody after durvalumab treatment. Thorac Cancer. 2023;14(19):1899–903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rojas-Marcos I, Graus F, Sanz G, Robledo A, Diaz-Espejo C. Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: case study. Neuro Oncol. 2007;9(1):75–7.

Article  PubMed  PubMed Central  Google Scholar 

Suero GO, Sola-Valls N, Escudero D, Saiz A, Graus F. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurología (English Edition). 2018;33(1):18–27.

Article  Google Scholar 

Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(8):1831–44.

Article  PubMed  Google Scholar 

Simard C, Vogrig A, Joubert B, Muniz-Castrillo S, Picard G, Rogemond V, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol-Neuroimmunol Neuroinflammation. 2020;7(3):e699.

Pittock SJ, Parisi JE, McKeon A, Roemer SF, Lucchinetti CF, Tan KM, et al. Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol. 2010;67(9):1109–15.

Article  PubMed  Google Scholar 

Gadoth A, Kryzer TJ, Fryer J, McKeon A, Lennon VA, Pittock SJ. Microtubule-associated protein 1 B: novel paraneoplastic biomarker. Ann Neurol. 2017;81(2):266–77.

Article  CAS  PubMed  Google Scholar 

Jitprapaikulsan J, Klein CJ, Pittock SJ, Gadoth A, McKeon A, Mills JR, et al. Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. J Neurol Neurosurg Psychiatry. 2020;91(3):328–30.

Article  PubMed  Google Scholar 

Tschernatsch M, Gross O, Kneifel N, Kaps M, Blaes F. SOX-1 autoantibodies in patients with paraneoplastic neurological syndromes. Autoimmun Rev. 2009;8(7):549–51.

Article  CAS  PubMed  Google Scholar 

Loehrer PA, Timmermann L, Pehl A, Bien CI, Pfestroff A, Pedrosa DJ. Rhombencephalitis associated with isolated Zic4-antibodies in paraneoplastic cerebellar degeneration: a case report. BMC Neurol. 2020;20(1):1–5.

Article  Google Scholar 

Duong SL, Pruss H. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics. 2022;19(3):848–63. An extensive review article about the pathophysiology of ICI-induced paraneoplastic disorders and discussion of current and future biologics therapies.

Article  PubMed  PubMed Central